{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:42:45Z","timestamp":1793083365972,"version":"4.5.0"},"reference-count":84,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Although development of biologics has importantly improved the effectiveness in inducing and maintaining remission in inflammatory bowel disease (IBD), biologic therapies still have several limitations. Effective, low-cost drug therapy with good safety profile and compliance is therefore a substantial unmet medical need. A promising target for IBD treatment strategies are Janus kinase (JAK) inhibitors, which are small molecules that interact with cytokines implicated in pathogenesis of IBD. In contrast to monoclonal antibodies, which are able to block a single cytokine, JAK inhibitors have the potential to affect multiple cytokine-dependent immune pathways, which may improve the therapeutic response in some IBD patients. Tofacitinib, inhibiting signaling via different types of JAKs, has been already approved for ulcerative colitis, and several other small-molecule are still under investigation. However, one of the main concerns about using JAK inhibitors is the risk of thromboembolic events. Moreover, patients with COVID-19 appear to have an increased susceptibility for immunothrombosis. Therefore, thrombotic complications may become a serious limitation in the use of JAK inhibitors in the SARS-CoV-2 pandemic. As many questions about safety and efficacy of small molecules still remain unclear, in our review we present the current data regarding approved JAK inhibitors, as well as those in clinical development for the treatment of IBD.<\/jats:p>","DOI":"10.3390\/jcm10235660","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T22:01:11Z","timestamp":1638309671000},"page":"5660","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-869X","authenticated-orcid":false,"given":"Patrycja","family":"Dudek","sequence":"first","affiliation":[{"name":"Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-4925","authenticated-orcid":false,"given":"Adam","family":"Fabisiak","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, 90-153 Lodz, Poland"},{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Zatorski","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, 90-153 Lodz, Poland"},{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-1807","authenticated-orcid":false,"given":"Ewa","family":"Malecka-Wojciesko","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-2712","authenticated-orcid":false,"given":"Renata","family":"Talar-Wojnarowska","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.pharep.2014.04.005","article-title":"Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases","volume":"66","author":"Sobczak","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1113\/JP275396","article-title":"The interplay between microbes and the immune response in inflammatory bowel disease","volume":"596","author":"Goethel","year":"2018","journal-title":"J. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","article-title":"IBD immunopathogenesis: A comprehensive review of inflammatory molecules","volume":"16","author":"Park","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: A review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: A systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ibd.21815","article-title":"Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts","volume":"18","author":"Magro","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/apt.12507","article-title":"Review article: Immunogenicity of anti-TNF biologics in IBD\u2014The role of patient, product and prescriber factors","volume":"38","author":"Moss","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"Tyler","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1381612825666190405141410","article-title":"JAK Inhibition: The Most Promising Agents in the IBD Pipeline?","volume":"25","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3748\/wjg.14.4280","article-title":"Role of cytokines in inflammatory bowel disease","volume":"14","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_14","first-page":"e1177","article-title":"Crohn\u2019s Disease and Ulcerative Colitis Show Unique Cytokine Profiles","volume":"9","author":"Nemeth","year":"2017","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2020.1780120","article-title":"JAK selectivity: More precision less troubles","volume":"14","author":"Roda","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Taxonera, C., Olivares, D., and Alba, C. (2021). Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review with Meta-Analysis. Inflamm. Bowel Dis., izab011.","DOI":"10.1093\/ibd\/izab011"},{"key":"ref_20","unstructured":"Overview (2021, July 13). Tofacitinib for Moderately to Severely Active Ulcerative Colitis. Guidance. NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ta547."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial","volume":"15","author":"Vermeire","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: Results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Sandborn","year":"2017","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14-e10","DOI":"10.1634\/theoncologist.2017-0665","article-title":"A Phase Ib\/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors","volume":"24","author":"Beatty","year":"2019","journal-title":"Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of Janus kinase inhibitors in inflammatory Bowel disease","volume":"11","author":"Wildenberg","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_28","unstructured":"(2021, March 10). Efficacy & Safety of TD-1473 in Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03758443?term=TD-1473&draw=2&rank=6."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients with Crohn\u2019s Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of Upadacitinib in a Randomized Trial of Patients with Active Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"ref_32","unstructured":"(2021, July 13). Filgotinib in Long-Term Extension Study of Adults with Crohn\u2019s Disease, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02914600."},{"key":"ref_33","unstructured":"(2021, July 13). Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn\u2019s Disease (SBCD), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03046056."},{"key":"ref_34","unstructured":"(2021, July 13). Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03077412."},{"key":"ref_35","unstructured":"(2021, July 13). Filgotinib in the Induction and Maintenance of Remission in Adults with Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914561."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"ref_37","unstructured":"(2021, July 14). A Phase II Study in Patients with Moderate to Severe Active Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03675477?draw=3."},{"key":"ref_38","unstructured":"(2021, July 14). A Phase II Study in Patients with Moderate to Severe Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03677648?recrs=a&cond=Crohn\u2019s+Disease&phase=1&draw=2."},{"key":"ref_39","unstructured":"(2021, February 12). Reistone Biopharma Positive Phase 2 Results for Reistone\u2019s JAK Inhibitor Demonstrate Significant Improvement in Patients with Moderate-to-Severe Ulcerative Colitis. Available online: https:\/\/www.prnewswire.com\/news-releases\/positive-phase-2-results-for-reistones-jak-inhibitor-demonstrate-significant-improvement-in-patients-with-moderate-to-severe-ulcerative-colitis-301222353.html."},{"key":"ref_40","unstructured":"(2021, February 12). Study of OST-122 in Patients with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04353791?term=OST-122&draw=2&rank=1."},{"key":"ref_41","unstructured":"(2021, March 10). BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease. ACR Meetings. Available online: https:\/\/acrabstracts.org\/abstract\/bms-986165-is-a-highly-potent-and-selective-allosteric-inhibitor-of-tyk2-blocks-il-12-il-23-and-type-i-interferon-signaling-and-provides-for-robust-efficacy-in-preclinical-models-of-systemic-lupus-e\/."},{"key":"ref_42","first-page":"5023","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"Am. Chem. Soc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","unstructured":"(2021, March 10). An Investigational Study of Experimental Medication BMS-986165 in Participants with Moderate to Severe Crohn\u2019s Disease, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03599622."},{"key":"ref_45","unstructured":"(2021, November 19). Safety and Efficacy of Deucravacitinib in Participants with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03934216."},{"key":"ref_46","first-page":"S758","article-title":"A Mechanism of Action for Cyclosporine a in Ulcerative Colitis: The Role of the Tec Kinase Itk in Disease Pathogenesis","volume":"152","author":"Weigmann","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3\/TEC Inhibitor, in Patients with Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_48","unstructured":"(2021, July 14). FDA Briefing Document, Arthritis Advisory Committee Meeting, 23 April 2018, NDA 207924, Baricitinib, Janus Kinase (JAK) inhibitor for RA, Eli Lilly and Company (Lilly), Available online: https:\/\/www.fda.gov\/media\/112372\/download."},{"key":"ref_49","first-page":"353","article-title":"JAK-STAT inhibitors for the treatment of immunomediated diseases","volume":"152","year":"2019","journal-title":"Med. Clin."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Angelini, J., Talotta, R., Roncato, R., Fornasier, G., Barbiero, G., Cin, L.D., Brancati, S., and Scaglione, F. (2020). JAK-inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules, 10.","DOI":"10.3390\/biom10071002"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"578314","DOI":"10.3389\/fimmu.2020.578314","article-title":"New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions","volume":"11","author":"Saidu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_52","unstructured":"(2021, July 14). A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03627052."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving Tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data from Global Clinical Trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf."},{"key":"ref_59","unstructured":"(2021, March 18). DA Approves Boxed Warning about Increased Risk of Blood Clots and Death with Higher Dose of Arthritis and Ulcerative Colitis Medicine Tofacitinib (Xeljanz, Xeljanz XR). FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: Long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1093\/ecco-jcc\/jjx180.400","article-title":"P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn\u2019s disease: Results from the CELEST study","volume":"12","author":"Panes","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients with Inflammatory Bowel Diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Seksik","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.gastro.2020.04.002","article-title":"Management of Patients with Crohn\u2019s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2468-1253(20)30121-7","article-title":"Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China","volume":"5","author":"An","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s10620-020-06624-5","article-title":"Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?","volume":"66","author":"Scribano","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","article-title":"Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study","volume":"69","author":"Bezzio","year":"2020","journal-title":"Gut"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2020.05.009","article-title":"SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California","volume":"159","author":"Gubatan","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_69","first-page":"85","article-title":"The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic","volume":"15","author":"Lodyga","year":"2020","journal-title":"Prz. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1053\/j.gastro.2020.05.066","article-title":"Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease","volume":"159","author":"Lukin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2020.04.059","article-title":"Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey from the European Crohn\u2019s and Colitis Organization","volume":"159","author":"Danese","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","article-title":"AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/gutjnl-2020-321244","article-title":"British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic","volume":"69","author":"Kennedy","year":"2020","journal-title":"Gut"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.cgh.2020.04.033","article-title":"Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies","volume":"18","author":"Hanzel","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sperger, J., Shah, K.S., Lu, M., Zhang, X., Ungaro, R.C., Brenner, E.J., Agrawal, M., Colombel, J.-F., Kappelman, M.D., and Kosorok, M.R. (2021). Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. Medrxiv Prepr. Serv. Health Sci.","DOI":"10.1101\/2021.01.15.21249889"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/ibd\/izaa303","article-title":"Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry","volume":"27","author":"Agrawal","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_78","unstructured":"Xeljanz (2021, July 13). Xeljanz XR (tofacitinib): Drug Safety Communication\u2014Due to an Increased Risk of Blood Clots and Death with Higher Dose. FDA, Available online: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death."},{"key":"ref_79","unstructured":"(2021, July 14). Increased Risk of Blood Clots in Lungs and Death with Higher Dose of Xeljanz (Tofacitinib) for Rheumatoid Arthritis. European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/news\/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: Combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5660\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:38:00Z","timestamp":1760168280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":84,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10235660"],"URL":"https:\/\/doi.org\/10.3390\/jcm10235660","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}